Annual report [Section 13 and 15(d), not S-K Item 405]

Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - Twist Bioscience (Details)

v3.25.1
Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - Twist Bioscience (Details)
$ in Thousands
 12 Months Ended
Oct. 21, 2024
USD ($)
item
Program
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Agreements      
Payments of consideration under RPAs, AAAs, and CPPAs   $ (53,000) $ (14,650)
Long-term royalty and commercial payment receivables under the cost recovery method   55,936 57,952
Short-term royalty and commercial payment receivables under the cost recovery method   413 $ 14,215
Royalty Purchase Agreement | Twist      
Agreements      
Contingent payments acquired (as a percent) 50.00%    
Payments of consideration under RPAs, AAAs, and CPPAs $ 15,000    
Maximum milestone payments entitled to receive $ 500,000    
Royalties entity has right to receive (as a percent) 50.00%    
Short-term royalty and commercial payment receivables under the cost recovery method   0  
Allowance for credit losses   $ 0  
Royalty Purchase Agreement | Twist | Maximum      
Agreements      
Number of early-stage programs | Program 60    
Number of partners associated with programs | item 30